The ABATE trial is studying the effects of a study vaccine named ACI-24.060 in people with early Alzheimer’s disease. A build-up of protein Abeta (Aβ) in the brain is believed to play an important role in cognitive decline in Alzheimer’s disease. ACI-24.060 is designed to help reduce the quantity of Aβ in the brain and may thereby have a positive effect on cognitive decline.
ABATE Part 1
Dementia and cognitive impairmentOpen for Recruitment
